Evidence map›Paper›PMID 31823290›Full record

ArticleCellular oncology (Dordrecht, Netherlands)2020

High IGF1R protein expression correlates with disease-free survival of patients with stage III colon cancer.

Aziz Zaanan, Claire Calmel, Julie Henriques, Magali Svrcek, Hélène Blons, Christèle Desbois-Mouthon, Fatiha Merabtene, Claire Goumard, Yann Parc, Brice Gayet and 6 more

Open access · greenAbstract read
In one paragraph

Article in Cellular oncology (Dordrecht, Netherlands), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 3 countries.

Aziz ZaananSorbonne Université, INSERM, Centre de Recherche Saint-Antoine, UMR_S938, F-75012, Paris, France. aziz.zaanan@aphp.fr.
Claire CalmelSorbonne Université, INSERM, Centre de Recherche Saint-Antoine, UMR_S938, F-75012, Paris, France.
Julie HenriquesMethodology and Quality of Life in Oncology Unit, INSERM UMR 1098, Besançon University Hospital, Besançon, France.
Magali SvrcekSorbonne Université, INSERM, Centre de Recherche Saint-Antoine, UMR_S938, F-75012, Paris, France.
Hélène BlonsDepartment of Biology, European Georges Pompidou Hospital, APHP, Paris Descartes University, Paris, France.
Christèle Desbois-MouthonSorbonne Université, INSERM, Centre de Recherche Saint-Antoine, UMR_S938, F-75012, Paris, France.
Fatiha MerabteneSorbonne Université, INSERM, Centre de Recherche Saint-Antoine, UMR_S938, F-75012, Paris, France.
Claire GoumardSorbonne Université, INSERM, Centre de Recherche Saint-Antoine, UMR_S938, F-75012, Paris, France.
Yann ParcSorbonne Université, INSERM, Centre de Recherche Saint-Antoine, UMR_S938, F-75012, Paris, France.
Brice GayetDepartment of Digestive, Oncological and Metabolic Surgery, Institut Mutualiste Montsouris, Paris Descartes University, Paris, France.
Julien TaiebDepartment of Gastroenterology and Digestive Oncology, European Georges Pompidou Hospital, APHP, Paris Descartes University, Paris, France.
Pierre ValidireDepartment of Pathology, Institut Mutualiste Montsouris, Paris Descartes University, Paris, France.
Christophe LouvetDepartment of Oncology, Institut Mutualiste Montsouris, Paris Descartes University, Paris, France.
Jean-François FléjouSorbonne Université, INSERM, Centre de Recherche Saint-Antoine, UMR_S938, F-75012, Paris, France.
Yves Le BoucSorbonne Université, INSERM, Centre de Recherche Saint-Antoine, UMR_S938, F-75012, Paris, France.
Françoise PrazSorbonne Université, INSERM, Centre de Recherche Saint-Antoine, UMR_S938, F-75012, Paris, France. francoise.praz@upmc.fr.ORCID http://orcid.org/0000-0002-5353-8889
Inserm · FRUniversité Paris Cité · FRCentre National de la Recherche Scientifique · FRDélégation Paris 5 · FR

Funding

Institut National Du Cancer 2010-1-FOR-05-INSERM
6 · The paper itself

Abstract

purposeThe aim of this study was to investigate the association between expression of insulin-like growth factor-1 receptor (IGF1R) and its ligand, IGF-II, and disease-free survival (DFS) in patients with stage III colon cancer (CC).

methodsIn this retrospective study we included consecutive patients who underwent curative surgery for stage III CC. IGF1R and IGF-II/IGF2 status were evaluated in tumour samples by immunohistochemistry and quantitative real-time PCR (qRT-PCR). Associations of markers with DFS were analysed using Cox proportional hazards models.

resultsHundred and fifty-one CC patients were included (median age, 66.6 years; female, 54.3%). Low levels of IGF1R and IGF-II protein expression were observed in 16.1% and 10.7% of the cases, respectively. No significant differences in clinicopathological characteristics between patients with tumours expressing low IGF1R or IGF-II protein levels and those with high levels were observed. A low IGF1R protein expression was found to be significantly associated with a shorter DFS (HR 3.32; 95% CI, 1.7-6.31; p = 0.0003), while no association was observed between IGF-II protein expression and DFS (HR 0.91; 95% CI, 0.28-2.96; p = 0.87). In a multivariate analysis, IGF1R protein status remained an independent prognostic factor for DFS (HR 2.73; 95% CI, 1.40-5.31; p = 0.003). Furthermore, we found that neither IGF1R nor IGF2 mRNA expression levels as measured by qRT-PCR correlated with the respective protein expression levels as assessed by immunohistochemistry. Neither of the mRNA expression levels was significantly associated with DFS.

conclusionsFrom our data we conclude that low IGF1R protein expression represents a poor prognostic biomarker in stage III colon cancer.

Indexed as

Gene Expression Regulation, NeoplasticAdultAgedAged, 80 and overColonic NeoplasmsDisease-Free SurvivalFemaleHumansImmunohistochemistryKaplan-Meier EstimateMaleMiddle AgedNeoplasm StagingReceptor, IGF Type 1Retrospective StudiesReverse Transcriptase Polymerase Chain ReactionIGF1R protein, humanReceptor, IGF Type 1RNA, MessengerColon cancerDisease-free survivalIGF1RIGF-II/IGF2KRAS/BRAFMSI

Identifiers

PMID31823290
PMCPMC12990689
OpenAlexW2995760132

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.